Therefore, cetuximab, an EGFR inhibitor, is the main targeted chemotherapy against metastatic CRC, although the cetuximab chemotherapy is limited to a subtype of CRC patients without mutated BRAF or KRAS genes. This evidence concerns the gene EGFR and colorectal carcinoma.